Skip to main content

Um in den USA zu traden, geh zu polymarket.us

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Technik·Südkorea

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Technik·Südkorea

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% Chance
Polymarket

$11,414 Vol.

13% Chance
Polymarket

$11,414 Vol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation agreement with Peptron for the SmartDepot microsphere platform remains limited to non-exclusive internal R&D on peptide candidates, including GLP-1 assets and expanded CNS indications, with no transition to a commercial licensing or technology transfer deal announced as the October 7, 2026 deadline approaches. The original 2024 pact, extended from an initial 14-month term, explicitly excludes binding commercial rights and permits termination on 30 days’ notice, while Lilly has separately advanced alternative long-acting delivery technologies such as Camurus’ FluidCrystal for incretin therapies. Recent executive comments from Peptron have highlighted completed initial validation and ongoing in-vivo work but provided no confirmation of imminent commercialization milestones, leaving traders with limited evidence of a near-term licensing outcome.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$11,414
Enddatum
7. Okt. 2026
Markt eröffnet
May 5, 2026, 8:02 PM ET

Abwickler

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation agreement with Peptron for the SmartDepot microsphere platform remains limited to non-exclusive internal R&D on peptide candidates, including GLP-1 assets and expanded CNS indications, with no transition to a commercial licensing or technology transfer deal announced as the October 7, 2026 deadline approaches. The original 2024 pact, extended from an initial 14-month term, explicitly excludes binding commercial rights and permits termination on 30 days’ notice, while Lilly has separately advanced alternative long-acting delivery technologies such as Camurus’ FluidCrystal for incretin therapies. Recent executive comments from Peptron have highlighted completed initial validation and ongoing in-vivo work but provided no confirmation of imminent commercialization milestones, leaving traders with limited evidence of a near-term licensing outcome.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$11,414
Enddatum
7. Okt. 2026
Markt eröffnet
May 5, 2026, 8:02 PM ET

Abwickler

0x65070BE91...

Verwandte

icon for Zulassungsantrag für Hautkrebsvakzine bis zum 30. Juni 2027 eingereicht?

Zulassungsantrag für Hautkrebsvakzine bis zum 30. Juni 2027 eingereicht?

88%
Ja
icon for Wird Retatrutide dieses Jahr von der FDA zugelassen?

Wird Retatrutide dieses Jahr von der FDA zugelassen?

3%
Ja
icon for Wird ein Hautkrebs-Impfstoff bis zum 31. Dezember 2027 von der FDA zugelassen sein?

Wird ein Hautkrebs-Impfstoff bis zum 31. Dezember 2027 von der FDA zugelassen sein?

65%
Ja

Vorsicht bei externen Links.

Häufig gestellte Fragen

„Eli Lilly licenses Peptron’s SmartDepot by October 7?" ist ein Prognosemarkt auf Polymarket, auf dem Händler „Ja"- oder „Nein"-Anteile kaufen und verkaufen, je nachdem, ob sie glauben, dass dieses Ereignis eintreten wird. Die aktuelle Wahrscheinlichkeit laut Community liegt bei 13% für „Yes". Wird „Ja" beispielsweise bei 13¢ gehandelt, schätzt der Markt die Wahrscheinlichkeit des Eintretens auf 13%. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen und Informationen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

Stand heute hat „Eli Lilly licenses Peptron’s SmartDepot by October 7?" ein Gesamthandelsvolumen von $11.4K generiert, seit der Markt am May 5, 2026 gestartet wurde. Dieses Aktivitätsniveau spiegelt starkes Engagement der Polymarket-Community wider und stellt sicher, dass die aktuellen Quoten von einem breiten Pool an Marktteilnehmern geprägt werden. Sie können Live-Preisbewegungen verfolgen und direkt auf dieser Seite auf jedes Ergebnis handeln.

Um auf „Eli Lilly licenses Peptron’s SmartDepot by October 7?" zu handeln, wählen Sie einfach, ob Sie glauben, dass die Antwort „Ja" oder „Nein" lautet. Jede Seite hat einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes widerspiegelt. Geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Wenn Sie „Ja"-Anteile kaufen und das Ergebnis als „Ja" aufgelöst wird, zahlt jeder Anteil $1 aus. Wird es als „Nein" aufgelöst, zahlen Ihre „Ja"-Anteile $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen, um einen Gewinn zu sichern oder einen Verlust zu begrenzen.

Die aktuelle Wahrscheinlichkeit für „Eli Lilly licenses Peptron’s SmartDepot by October 7?" liegt bei 13% für „Yes". Das bedeutet, die Polymarket-Community glaubt derzeit, dass eine Wahrscheinlichkeit von 13% besteht, dass dieses Ereignis eintritt. Diese Quoten werden in Echtzeit auf Basis tatsächlicher Handelsgeschäfte aktualisiert und liefern ein ständig aktualisiertes Signal dessen, was der Markt erwartet.

Die Auflösungsregeln für „Eli Lilly licenses Peptron’s SmartDepot by October 7?" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.